Erectile dysfunction is a condition affecting 1 in every 10 men. Although its occurrence is related to ageing, illness and its necessary therapy can play a major role. Prostate cancer can lead to erectile dysfunction both psychologically through depression and emotional distress, and physically through therapy for the disease. An international quality of life survey involving 401 patients with prostate cancer was conducted. The objectives of the study were to investigate the patients' understanding of the treatment options they received, to explore the importance of the patient±doctor communication in the treatment of prostate cancer and to see what effect treatment had on patient's sexual function.
Introduction
Studies indicate that 1 in 10 men are affected by erectile dysfunction, a condition often referred to somewhat pejoratively as impotence. 1, 2 Although for some men erectile dysfunction may not be the most important measure of sexual satisfaction, for many men, erectile dysfunction creates mental stress that affects their interactions with family and associates. 3 Erectile dysfunction is often assumed to be a natural consequence of the ageing process, to be tolerated along with other conditions associated with ageing. However, for the elderly as well as others, erectile dysfunction may occur as a consequence of a speci®c illness or of medical treatment for that illness, as is the case in prostate cancer. This can often result in fear, loss of image and self-con®dence, and depressive illness. Loss of libido is also an important component of the altered sexuality of men suffering from prostate cancer and is particularly common in those treated with androgen deprivation therapy.
Prostate cancer
Prostate cancer is the most common form of cancer in men and is second only to lung cancer as a cause of cancer deaths. 4, 5 The highest mortality rate of prostate cancer is found in Switzerland; during 1990 ±1993, the age-adjusted death rate was 22.5 per 100 000 capita. This is followed by Sweden with a rate of 21.1. 5 In the USA, prostate cancer is now the most frequently diagnosed male cancer, with an estimated 317 000 new cases and 41 400 deaths in 1996. 5 Although Japan has an incident rate just one-tenth of that experienced in the USA, recent data shows that this is now rising rapidly, which may be due to an increasingly westernised lifestyle. 6 Prostate cancer is primarily a disease affecting men beyond the age of 50. 4 More than 80% of all cases are diagnosed in men aged over 65 y, 7 with a median age at diagnosis of 72 y. 8 In addition, the worldwide trend towards an ageing population means that the number of prostate cancer deaths is predicted to increase markedly during the next two decades.
There are various psychological causes for erectile dysfunction in prostate cancer patients, in addition to the disease itself and the effects of therapies. Some patients cease sexual activity on the assumption that it will be painful or that it will stimulate the cancer itself, while others fear irrationally that they might pass the cancer on to their partners. Clearly, prostate cancer can result in depression, a potent cause of loss of libido and erectile dysfunction. 9 In general terms, both the patient and his family will have to face emotional distress and changes to their lifestyle, brought about by the cancer itself as well as the resultant therapy.
Prostate cancer therapy
Therapeutic options for prostate cancer include watchful waiting, hormonal therapy, radiotherapy and surgery, the choice being dependent on the stage of disease ( Table 1) . The treatment aim in localized prostate cancer is cure and the therapy undertaken very much depends on the patient category. For example, watchful waiting may be more appropriate in older men with limited life expectancy, as opposed to surgery for men whose life expectancy is greater than 10 y.
The main therapeutic option for locally advanced disease is hormonal therapy. The administration of luteinizing hormone-releasing hormone (LHRH) analogues (for example, goserelin, buserelin and leuprolide) alone or together with an antiandrogen (for example,¯utamide, bicalutamide and nilutamide) results in androgen ablation, which has been shown to effectively reduce PSA level, prostate volume and tumour burden. Neoadjuvant hormonal therapy may be used prior to radiotherapy or radical prostatectomy to reduce tumour volume. Alternatively, watchful waiting may be appropriate for older patients, particularly in the presence of other signi®cant illnesses.
In metastatic disease, the main therapeutic option is hormonal therapy with either orchidectomy or an LHRH analogue. More recently, antiandrogens have been used. Unfortunately, treatment for metastatic disease is palliative and not curative.
Quality of life survey
Prostate cancer may take many years to progress and, as a consequence, the long-term nature of treatment strategies places a high level of importance on quality of life issues. To investigate these issues, an international survey was conducted involving 401 patients in four countries: UK, Germany, Italy and USA. The objectives of the survey were to investigate the patients' understanding of the treatment options they received, to explore the importance of the patient±doctor communication in the treatment of prostate cancer and to see what effect treatment had on patient's sexual function.
Patients were recruited to the study mainly through their clinicians and had a con®rmed diagnosis of prostate cancer. All patients who agreed to participate in the study completed the questionnaire. The survey itself was developed in consultation with an international project steering committee and a pilot study involving 23 patients was conducted in the UK. Two questionnaires were developed; one explored quality of life issues and the other sexual interests. Information was gathered through direct face-to-face interviews, many of which were conducted within the clinic. The sexual function questionnaire was completed in private by the patient.
Quality of life issues
Approximately equal numbers of patients were recruited from the four participating countries. The average age was 67 y and the majority of patients were aged 71±75 y (35%). The percentage of other age categories was: 48 ±60 y: 16%; 61 ±65 y: 16%; 66 ±70 y: 30%; and over 76 y: 2%. Patients' marital status was as follows: married, 75%; living alone, 20%; and living with partner, 5%. The majority of patients had been diagnosed with prostate cancer within the previous 3 y (range 1±16 y).
With regard to the patients' perception of treatment options, almost half (48%) of patients surveyed considered that they were not given an option on initial diagnosis. This percentage varied between countries and was as high as 86% in the UK and 75% in Italy. In contrast, only 16% of patients in both Germany and the USA felt that they had not been offered treatment options.
The incidence of speci®c side-effects was included in the questionnaire. Overall, the major side-effect experienced by patients following medication or surgery for prostate cancer was loss of libido (71%), followed by hot ushes (45%) and incontinence (45%) (Figure 1 ). Diarrhoea and chest tenderness accounted for 16% and 13% of reported side-effects, respectively. Patients were also questioned about the lifestyle changes they had experienced after diagnosis, medication or surgery. The most frequently reported change was a reduction in going out or travelling, followed by patients becoming more withdrawn or socialising less ( Table 2) . A reduction in sex life was reported more frequently following surgery than after diagnosis or medication, while depression, mood swings or irritability was reported as being more common after medication than after diagnosis or surgery. Patients generally felt less active, requiring more rest following either form of treatment. Other lifestyle changes recorded are shown in Table 2 . More speci®cally, patients were asked if they had discontinued any hobbies following the diagnosis of prostate cancer. The top ®ve hobbies discontinued were: sports activities (28%), gardening (14%), cycling (12%), travelling (8%) and walking (8%).
Sexual interest
Patients were asked whether they were given sexual advice or help by a number of healthcare professionals after diagnosis or after treatment. Overall, of the ®ve categories of healthcare professional enquired about, hospital doctors were cited as giving advice by 46% of patients, general practitioners by 21%, sex therapists by 9%, other professionals by 7% and nurses by 3%. On a country basis, the hospital doctor was more likely to give advice in the USA, Germany and Italy, while in the UK it was more likely to be a sex therapist (Figure 2 ). The provision of reading material on sexual activity following diagnosis was also investigated. Overall, 23% of patients said that they had received material; the reported occurrence in each of the countries was: USA, 39%; Germany, 21%; Italy, 18%; and UK, 10%. With regard to patients who would ®nd sex counselling helpful to themselves or their partner, 46% of all patients said that they would (Figure 3 ). More patients in the USA said that they would ®nd counselling useful than in the other countries.
Changes in sexual activity before diagnosis and during the last four weeks were analysed. Patients were asked about four activities: passionate kissing, sexual touching, sexual intercourse and masturbation. A reduction in the frequency of all of these except for masturbation, which occurred rarely before diagnosis, was recorded (Figure 4) . The greatest decrease in activity was recorded in sexual touching: 26% of patients reported this activity twice per week before diagnosis compared with 45% who said they never or rarely did in the last month. Patients were questioned about how their sexual potency compared before and after diagnosis. In the three aspects of sexual intercourse studied, that is, maintenance of erection, full penetration and orgasm, the majority of patients reported that these activities were not as easy now as before Figure 2 Patients given advice by different medical professionals according to country. diagnosis: 70%, 69% and 68% of patients for each of the activities, respectively. A comparison was made in the overall level of sexual interest and activity before diagnosis, three months after diagnosis and in the last month. Patients scored their level of interest on a scale of 1±10, with not interested scoring between 0 and 3, some interest scoring 4±7 and a score of 8±10 given for very interested. Sexual activity was scored in a similar way, with scores of 1±3 implying no activity, 4±7 some activity and 8±10 frequent activity. Analysis of data indicated a reduction in score following diagnosis for both sexual interest and sexual activity ( Figure 5 ). Data on sexual activity were strati®ed according to patient age. A decline in level of sexual activity following diagnosis was noted in each of the patient age groups studied ( Figure 6 ). The level of sexual interest correlated with age, with patients aged 48±60 y having the greatest level of sexual interest and patients aged over 76 y having the lowest. Patients were asked whether they would like their sexual activity to be higher. Overall 65% of patients expressed a preference for a higher level of sexual activity ( Figure 7) . Patients aged 61±65 y expressed the highest preference for an increase in activity (74%) and those aged over 76 y the lowest (38%). This can be put into the context of sexual activity before diagnosis, three months after diagnosis and in the last month according to age or country (Figure 8 ). Clearly patients of all ages and in each of the countries studied would prefer their sexual activity to be the same as it was before diagnosis or even higher.
Discussion
One of the major ®ndings of this international survey of men with prostate cancer was that too little counselling or information on treatment options and their effects on sexual function is provided to patients. The level of information supplied to patients varied from country to country, with patients in the USA and Germany being better counselled than those in the UK and Italy. Clearly, patients do feel a need to discuss the consequences of treatment on sexual function. Almost half of the patients in the survey felt that sex counselling, in particular, would be helpful.
A signi®cant ®nding of the survey was that prostate cancer therapy has a de®nite impact on patients' general lifestyle. Patients expressed a feeling of becoming withdrawn and having a reluctance to go out and socialise. Another important lifestyle change recorded was the discontinuation of hobbies, such as sporting activities, Figure 5 Comparison of the level of sexual interest and activity before diagnosis, in the three months following diagnosis and in the last month. Figure 4 Comparison of the frequency of sexual activities before diagnosis and in the last month. Figure 6 Comparison of sexual activity following diagnosis according to age.
Figure 7
Patients who would prefer higher sexual activity according to age.
gardening and cycling. Therapy also had a signi®cant impact on sexual function and activity, and side-effects such as loss of libido and hot¯ushes were frequently reported following either medical therapy or surgery. Patients appeared to have less interest in sex following diagnosis of prostate cancer. In terms of actual sexual activity, a reduction in frequency of three sexual activities was recorded: passionate kissing, sexually touching and sexual intercourse. Sexual potency also declined, with the majority of patients having greater dif®culty in maintaining an erection and achieving full penetration and orgasm.
Previous studies have reported long-term impotence rates of 20±30% following radiotherapy for prostate cancer, possibly due to damage of the neurovascular supply to the corpora. 10 A 90% incidence of erectile dysfunction after radical prostatectomy was not uncommon. However, with the development of a nerve-sparing technique by Walsh and Donker, 11 86% of younger patients have been reported to remain potent postoperatively. 12 Other data indicate that men with normal erectile function are more likely to retain this function after radiotherapy than after radical prostatectomy. 13 Testosterone appears to be necessary for the maintenance of libido in both men and women.
14 Drugs which signi®cantly decrease testosterone synthesis or block utilization have been associated with decreased libido. 15 LHRH analogues reduce serum testosterone levels, while antiandrogens competitively inhibit the binding of testosterone and dihydrotestosterone to the androgen receptor thereby blocking the stimulatory activity of the two steroidal androgens. Steroidal antiandrogens also inhibit LHRH secretion resulting in a reduction of testosterone secretion.
The option of monotherapy with non-steroidal antiandrogens, such as¯utamide, nilutamide and bicalutamide, has recently been explored. These compounds do not inhibit LHRH secretion and so do not reduce testosterone production. Instead they may increase testosterone levels by blocking negative feedback of testosterone at the hypothalamus and pituitary. Results to date with¯uta-mide and nilutamide show that libido and potency may be retained in 70 ±80% of patients. 16, 17 Monotherapy with bicalutamide similarly appears to provide positive bene®ts in terms of quality of life (data on ®le). Oestrogens mainly decrease libido in males because of their ability to reduce circulating androgen levels. 18 Orchidectomy is associated with a loss of libido, erectile dysfunction and hot¯ushes. In addition, patients have to endure the psychological impact and loss of body image associated with castration.
Patients in the present survey expressed dissatisfaction with their reduced level of sexual activity after therapy and the majority of patients stated that they would prefer the level to be higher. Indeed, their preferred level was higher than that before diagnosis. This observation was valid for each of the countries and age categories studied. Although it is dif®cult to measure, the importance of regular, satisfactory sexual activity in maintaining quality of life and self-esteem should not be underestimated. Men beyond middle age, as is often the case in those suffering from prostate cancer, are particularly reliant on the social support of intimate relationships. Withdrawal from sexual relationships may have a very negative impact, not only on their enjoyment of life, but also on their general health. Erectile dysfunction and loss of libido can lead to loss of body image and damage to relationships. Unwillingness to discuss the problem openly or to seek help only serves to compound the problem.
With regard to sexual function, previous quality of life questionnaires appear to have severe failings. Another inherent problem with such questionnaires is that older patients ®nd sexual function a dif®cult issue to discuss. Due to these de®ciencies the full effect of prostate cancer on sexual function is dif®cult to assess and the overall impact of prostate cancer on sexual function may be greater than is currently thought. The present questionnaire has gone some way to overcome these problems. Although a great deal of information has been gathered on the effects of prostate cancer therapy on patients' sexual function, the present survey did not identify whether surgical or medical therapy impacted more on sexual function. Clinically, these treatment options have been shown to be associated with varying degrees of impotence and reduced libido. Future research should address this issue by grouping patients into medical and surgical treatment categories and identifying the speci®c effects of therapy on sexual function.
Conclusions
This survey con®rms that the diagnosis of prostate cancer and the therapy required is associated with a reduced quality of life. It also indicates that there is a need for improved communication between treating physicians and patients regarding treatment options, counselling advice, support groups and literature. Patient involvement in informed treatment decision will help promote a more positive attitude and an improved quality of life. In addition, new potency preserving treatments may potentially improve quality of life for prostate cancer sufferers by maintaining this important aspect of their lives without compromising the therapeutic ef®cacy of treatment.
